The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has decided to venture into the real estate sector with the ...

The insulin glargine and lixisenatide combination is ... 1/2 cup of juice or regular (non-diet) soda 1 tablespoon of honey three or four pieces of hard candy glucose (sugar) tablets For severe ...

Regular insulin, which is often used in pregnancy ... At present no reports on glulisine use in pregnancy are available. [53] Insulin Glargine. The first long-acting insulin analogue was approved ...

Each group comprised 30 patients. Group G received regular insulin alongside insulin glargine, Group D was treated with regular insulin and insulin degludec, while Group R was managed using only ...

Regular exercise is critical for managing ... Other options include: A synthetic form of insulin called Semglee (insulin glargine) is available. This long-acting form can be substituted for ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo ... without any prescriber intervention like a regular generic drug. Civica's move has been welcomed ...

Background: Diabetic ketoacidosis (DKA) is an endocrine emergency with associated risk of morbidity and mortality. Despite this, DKA management lacks strong evidence due to the absence of large ...

often used with injectable long-acting insulin Afrezza (inhaled insulin) Regular-/short-acting 30 minutes Three to six hours Usually taken 30 to 60 minutes before a meal Humulin R, Novolin R, ...

All patients with T1DM were using multiple daily insulin injections (NPH or glargine combined with regular insulin or aspart/lispro). Capillary blood glucose levels measured before and immediately ...

Background: The lockdown at the start of coronavirus disease 2019 (COVID-19) pandemic in Saudi Arabia (March 2020 to June 2020) shifted routine in-person care for patients with type 2 diabetes ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.